Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 12;7:11353. doi: 10.1038/s41598-017-11378-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Comparison of RA patients with or without add-on DXM therapy. (a) The comparison of EULAR therapeutic response assessed at the 6^th month between RA patients with or without add-on DXM therapy was determined by Fisher’s exact test. The changes in disease activity parameters including (b) DAS28, (c) CRP levels, the levels of proinflammatory cytokines in serum including (d) TNF-α, (e) IL-6, (f) IFN-γ, and (g) IL-17A after 6-month therapy with add-on DXM in RA patients. The data were presented as box-plot diagrams, with the box encompassing the 25^th percentile (lower bar) to the 75^th percentile (upper bar), and the horizontal line within the box indicated the median value. (h) The comparison of the decrement of TNF-α, IL-6, IFN-γ and IL-17A levels between patients with or without add-on DXM therapy. Data were presented as mean ± SEM. *p < 0.05, **p < 0.005, versus before treatment, determined by the Wilcoxon signed rank test.